S-Gboxin is a small molecule inhibitor that targets mitochondrial ATP synthase, particularly in certain cancer cells. It has been investigated for its potential as an anticancer agent due to its ability to disrupt energy production in tumor cells. By selectively inhibiting ATP synthase, S-Gboxin reduces ATP levels, leading to impaired cell growth and induction of cell death in specific cancer types. Research has shown it to be active against glioblastoma and other solid tumors in preclinical models. Its selectivity for cancer cell mitochondria makes it a promising candidate for further development in targeted cancer therapies. Studies are ongoing to evaluate its efficacy, pharmacokinetics, and potential for use in combination with other anticancer drugs.